How to Fast‑track Patent Protection in Singapore After the SG Patents Fast Suspension (2026)

Last updated: 3 May 2026

With the Intellectual Property Office of Singapore (IPOS) suspending new requests under SG Patents Fast with effect from 4 January 2026, patent applicants across Singapore need to identify workable alternatives to SG Patents Fast immediately. The suspension, announced while IPOS reviews the programme, removes the most popular domestic acceleration route that had offered a first office action within four or eight months of request. For startups racing to secure funding, multinationals coordinating global portfolio filings, and SMEs defending market positions, the practical effect is a material lengthening of examination timelines unless other expedited pathways are engaged promptly.

TL;DR, Three fastest alternatives to SG Patents Fast right now:

• Patent Prosecution Highway (PPH): If you hold a favourable office action or allowance from a partner office, a PPH request at IPOS can deliver a first office action in roughly 3–6 months.
• ASPEC (ASEAN Patent Examination Co‑operation): Leverage search and examination results from any ASEAN partner office to target a first office action within approximately 4–9 months.
• Examiner interviews and focused claim amendments: Proactive prosecution tactics, including early examiner engagement, can compress response cycles to 2–8 months depending on case complexity.

What IPOS Announced and What Changed

SG Patents Fast launched on 20 May 2025 as the successor to the SG IP FAST pilot programme, which concluded on 31 December 2024. The new programme offered two tiers of acceleration, a four‑month track and an eight‑month track to first office action, with simplified eligibility criteria and transparent fee structures. It replaced the earlier pilot with broader applicant access and was part of Singapore’s IP Strategy 2030 (SIPS 2030) push to reinforce the city‑state’s position as an intellectual property hub.

However, IPOS announced that it is reviewing the SG Patents Fast and SG Trade Marks Fast acceleration programmes and, with effect from 4 January 2026, will not accept new requests under either programme. Existing requests that were already accepted before that date continue to be processed under the original programme timelines. The review period has no announced end date, leaving applicants in an indefinite holding pattern for domestic acceleration.

Key Dates and What They Mean for Pending Requests

The critical timeline for practitioners is as follows. The SG IP FAST pilot ended on 31 December 2024. SG Patents Fast launched on 20 May 2025. Suspension of new requests took effect on 4 January 2026. Requests filed and accepted before 4 January 2026 remain in the queue and should proceed under original service standards. No reinstatement date has been published. Industry observers expect the review to last at least several months, making it essential for applicants with pending or planned filings to evaluate patent filing alternatives in Singapore without delay.

Who Is Affected?

The SG Patents Fast suspension affects any patent applicant who had planned to request accelerated examination through the domestic IPOS programme. This includes Singapore‑based startups preparing to file national‑phase applications, overseas companies entering Singapore via PCT national phase, and patent attorneys advising clients who relied on the four‑ or eight‑month acceleration window. Any applicant who has not yet filed a formal acceleration request with IPOS must now pivot to one of the alternative routes outlined below.

Quick Decision Checklist, Who Should Act and How

Time is critical. Use this six‑step checklist to determine your best patent prosecution strategy for Singapore in 2026:

1. Audit priority dates. Identify the earliest priority date for every pending Singapore application. Applications approaching lapse deadlines or critical commercial milestones need immediate attention.
2. Map your patent family. Check whether any family member has received a favourable office action or grant in a PPH partner office (e.g., USPTO, EPO, JPO, KIPO, IP Australia). If so, PPH is likely your fastest route.
3. Evaluate PCT work products. If you entered Singapore via the PCT route, confirm whether you have a positive International Search Report (ISR) or favourable Written Opinion (WO) that can be cited to expedite national‑phase examination.
4. Consider ASPEC eligibility. If any ASEAN patent office has issued search or examination results for the same invention, the ASPEC pathway can accelerate prosecution with minimal additional cost.
5. Assess trade‑secret viability. For inventions where patent timelines have become untenable, evaluate whether trade‑secret protection or defensive publication offers adequate interim coverage.
6. Budget for alternatives. Factor in PPH preparation costs, possible translation fees, and counsel time for examiner interviews and claim amendments.

Tailored guidance by applicant type:

• Startups: Prioritise PCT filing timing and provisional‑to‑PCT conversion strategies. Where budget is tight, a selective PPH request in one key jurisdiction (e.g., USPTO) can unlock fast Singapore prosecution later. Defensive publication may protect freedom to operate while timelines extend.
• SMEs: Focus on mapping existing family grants. A single allowed US or Australian patent can serve as the springboard for a PPH request, which is often the most cost‑effective route to expedite patent examination in Singapore.
• Large corporates and multinationals: Deploy divisional filing strategies alongside PPH requests. Coordinate examiner interviews across jurisdictions to align claim scope, and ensure prosecution decisions do not inadvertently narrow claims needed for enforcement in key markets.

Practical Alternatives to SG Patents Fast

With SG Patents Fast suspended, five principal routes remain available to accelerate patent grant in Singapore. The choice depends on your patent family history, budget, commercial urgency, and enforcement priorities. Below is a route‑by‑route breakdown, followed by a comparison table summarising estimated patent timelines in Singapore for each option.

Patent Prosecution Highway (PPH / PCT‑PPH)

The PPH is now the single most powerful alternative to SG Patents Fast for applicants with international patent families. Under the PPH framework administered through WIPO and bilateral agreements, an applicant who has received a favourable determination (an allowance, grant, or indication of allowable claims) from a partner patent office can request expedited examination at IPOS based on that work product.

IPOS participates in PPH arrangements with major offices including the USPTO, EPO, JPO, KIPO, CNIPA, and IP Australia, among others. The PCT‑PPH variant allows applicants to rely on a favourable Written Opinion or International Preliminary Report on Patentability (IPRP) from a PCT International Authority.

Eligibility requires that the Singapore claims sufficiently correspond to those found allowable or patentable by the partner office. Applicants must submit the partner‑office work product, a claims correspondence table (mapping Singapore claims to allowed foreign claims), and any required translations. Once accepted, industry observers expect a first office action within approximately 3–6 months, broadly comparable to the faster tiers that SG Patents Fast previously offered.

Action steps: Identify any family member with a favourable determination; prepare a claims correspondence table; file the PPH request with IPOS along with supporting documentation.

ASEAN Patent Examination Co‑operation (ASPEC)

ASPEC enables work‑sharing among ASEAN patent offices. If a search or examination report has been issued by any participating ASEAN member, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand, and Vietnam, the applicant can request that IPOS consider those results when examining the corresponding Singapore application.

The programme is free of charge (no IPOS surcharge for ASPEC requests), making it one of the most cost‑effective alternatives to SG Patents Fast. Early indications suggest that ASPEC requests can yield a first office action within approximately 4–9 months, depending on the partner office and the quality of the cited work product. ASPEC is particularly useful for applicants filing across multiple ASEAN jurisdictions simultaneously.

PCT National‑Phase Strategies

Applicants entering Singapore via PCT national phase can leverage their international work products to expedite examination. A positive ISR or favourable WO can be submitted alongside the national‑phase entry to help focus the examiner’s review and reduce the number of examination cycles required. Timing the national‑phase entry strategically, for instance, entering closer to the 30‑month deadline after accumulating favourable international reports, can give the IPOS examiner a stronger evidentiary foundation, potentially reducing prosecution time to 6–12 months for a first office action. Coordinating PCT chapter II (demanding an IPRP) before national entry is another tactic that can accelerate the Singapore phase.

Examiner Engagement Tactics

Proactive engagement with IPOS examiners remains available regardless of programme suspensions. Requesting an examiner interview, either by telephone or in person, to discuss prior art, claim scope, and potential amendments before a formal office action can resolve objections faster than sequential written exchanges. Filing focused claim sets that closely track allowable subject matter identified in partner‑office actions, and submitting voluntary amendments early, are proven prosecution tactics that can compress examination timelines to 2–8 months. These strategies are especially effective when combined with a PPH or ASPEC request.

Provisional Filings, Divisional Strategy, and Defensive Options

Where grant timelines remain too long, applicants should consider provisional filings to secure priority dates, divisional applications to protect specific claim sets, and, where appropriate, trade‑secret protection or defensive publication to preserve freedom to operate while patent prosecution continues.

At‑a‑Glance Comparison of Patent Filing Alternatives in Singapore

Estimated Timelines and Worked Examples

Understanding how these alternatives to SG Patents Fast play out in practice requires scenario modelling. Below are three worked examples illustrating typical timelines for different applicant profiles.

Scenario 1: Startup, Provisional → PCT → PPH

A Singapore‑based biotech startup filed a provisional application in March 2025, followed by a PCT application in March 2026. The PCT International Search Report, received around September 2026, is broadly favourable. The startup enters Singapore national phase in October 2026 and simultaneously files a US national‑phase application. If the USPTO issues a notice of allowance by approximately April 2027, the startup files a PPH request at IPOS the same month. Under this trajectory, a first IPOS office action could arrive by roughly July–October 2027, approximately 3–6 months after PPH acceptance. Total timeline from provisional filing to Singapore first office action: roughly 28–31 months.

While not as compressed as the old four‑month domestic track, this is significantly faster than the standard IPOS examination queue.

Scenario 2: SME, Granted US Parent → PPH Singapore

An electronics SME has an allowed US patent (granted December 2025) for a sensor technology and a pending Singapore national application filed in May 2025. Upon learning of the SG Patents Fast suspension, the SME’s counsel files a PPH request at IPOS in January 2026, accompanied by the US grant certificate, claims correspondence table, and all relevant prior‑art references. IPOS accepts the PPH request and issues a first office action by approximately April–July 2026. Assuming responsive prosecution (one round of amendments), grant could follow by late 2026 or early 2027. Total incremental delay versus what SG Patents Fast would have delivered: likely 2–4 months at most, a manageable variance for most commercial timelines.

Scenario 3: Multinational, Divisional + Examiner Interview

A multinational pharmaceutical company has a parent Singapore application with broad claims under examination and needs to carve out a divisional application for a specific formulation claim set. The company files the divisional in February 2026, voluntarily submits focused claims aligned with claims allowed by the EPO, and requests an examiner interview with IPOS in March 2026. The examiner interview resolves prior‑art objections in April 2026, and a favourable first office action issues in May–June 2026. Grant of the divisional may follow within 4–8 months of filing. Meanwhile, the parent application continues through standard prosecution. This dual‑track approach, divisional for speed, parent for breadth, mitigates the enforcement risk of relying on a single narrowed claim set.

Costs, Documentation and Procedural Checklists

Each alternative route to accelerate patent protection in Singapore carries its own documentation and fee requirements. Planning these in advance avoids unnecessary delays once you commit to a pathway.

General cost bands (counsel fees excluded):

• PPH request: Low to medium, official IPOS filing fees are modest; primary cost is preparation of claims correspondence tables and, where needed, translations.
• ASPEC request: Low, IPOS does not charge a surcharge; the main outlay is assembling partner‑office work products.
• PCT national‑phase entry: Medium, standard national‑phase fees plus examination request fees apply; no acceleration surcharge.
• Examiner interviews: Low, IPOS does not charge for interview requests; counsel preparation time is the primary cost.
• Divisional filings: Medium to high, full filing and examination fees for a new application.

How to Prepare PPH Requests (Evidence List)

A well‑prepared PPH request dramatically increases the likelihood of acceptance and fast processing. Compile the following before filing:

• Claims correspondence table: A side‑by‑side mapping showing how each Singapore claim sufficiently corresponds to claims found allowable by the partner office.
• Partner‑office work product: Copy of the office action, search report, or grant certificate from the office of earlier examination (e.g., USPTO, EPO, JPO).
• Prior‑art references: All references cited by the partner office during examination.
• Translations: English translations of any non‑English documents (required by IPOS).
• Amended claims (if needed): Singapore claims may need to be amended to align with the allowed partner‑office claims before filing the PPH request.

Guidance on PPH documentation requirements is published by WIPO and by IPOS on its acceleration programmes page. Practitioners should check for updates, as requirements may evolve during the SG Patents Fast review period.

Litigation and Claim Drafting Considerations When Accelerating

Speed in prosecution must be balanced against enforceability. Accelerated routes, particularly PPH, typically require narrowing Singapore claims to correspond with those allowed abroad. While this can be acceptable for many commercial purposes, it may create vulnerabilities in subsequent infringement proceedings if competitors design around the narrower claim scope.

Key risks to manage include the following. Claim amendments made during accelerated prosecution may generate prosecution history estoppel, limiting the scope of equivalents available in litigation. Rapid prosecution may leave less time to identify and address prior art, potentially weakening the patent’s validity position. Coordinating claim scope across jurisdictions is essential, a claim that is commercially valuable in Singapore may need to be broader or differently framed than the claim allowed by a foreign partner office.

The likely practical effect is that applicants should treat accelerated prosecution as a strategic choice, not merely a procedural one. Counsel experienced in both prosecution and enforcement should review claim amendments before they are filed, ensuring that speed does not come at the cost of rights that matter in litigation. Where a patent is likely to be asserted, industry observers recommend maintaining a parallel application with broader claims under standard prosecution timelines as a hedge.

When to Consult Counsel, Recommended Next Steps

The SG Patents Fast suspension demands an active response, not a wait‑and‑see approach. Each month of inaction is a month added to your examination queue. To take the right next step, prepare the following for your initial consultation:

• A list of all pending Singapore applications with priority dates and current prosecution status.
• Details of any related patent family members, including jurisdictions and prosecution outcomes (grants, allowances, or favourable office actions).
• Your most urgent commercial deadlines, product launches, licensing negotiations, funding rounds, or enforcement needs.
• A list of target markets beyond Singapore where co‑ordinated prosecution may be required.

Armed with this information, experienced intellectual property counsel can map the optimal combination of alternatives to SG Patents Fast for your specific portfolio and commercial situation.

Sources

1. Intellectual Property Office of Singapore, Acceleration Programmes
2. IPOS, Circular: New Patents and Trade Marks Acceleration Programmes
3. Baker McKenzie InsightPlus, Singapore IPOS Launches New Patents and Trade Marks Programmes
4. Rajah & Tann Asia, New Patents and Trade Marks Acceleration Programmes
5. Marks & Clerk, Singapore IP Practice Updates
6. APAA, How to Short‑Cut Patent Prosecution in ASEAN
7. WIPO, Patent Prosecution Highway
8. Finnegan, How to Fast‑Track Patents in the U.S. and Globally
9. Asia IP, Singapore IP Guide 2025